• Users Online: 154
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 


 
 Table of Contents  
STUDY PROTOCOL
Year : 2018  |  Volume : 3  |  Issue : 3  |  Page : 101-105

High focused Evaluation of Atherosclerotic risk profile in Retinal Thrombosis: Vascular events Incidence, Sex involvement and Interventional outcomes assessed by Ophthalmologists and internists Network – HEART VISION study protocol


1 Department of Internal Medicine and Medical Specialties and Research Center on Gender and Evaluation and Promotion of Quality in Medicine (CEQUAM), Sapienza-University of Rome, Rome, Italy
2 Department of Sense Organs, Sapienza-University of Rome, Rome, Italy
3 Department of Computer, Control, and Management Engineering Antonio Ruberti, Sapienza-University of Rome, Rome, Italy
4 Centre for Outcomes Research and Evaluation (CORE) McGill University Health Centre Research Institute, Montreal, Canada; Department of Experimental Medicine, Sapienza-University of Rome, Rome, Italy

Date of Submission02-Jun-2018
Date of Decision13-Jul-2018
Date of Acceptance20-Jul-2018
Date of Web Publication23-Oct-2018

Correspondence Address:
Marco Proietti
IRCCS Istituto di Ricerche Farmacologiche “Mario Negri”, Milan
Italy
Login to access the Email id

Source of Support: This study was funded by Sapienza-University of Rome in 2014 -C26A147HC8., Conflict of Interest: None


DOI: 10.4103/2542-3975.235145

Rights and Permissions
  Abstract 

Background and objectives: Retinal vein occlusion (RVO), one of the most relevant causes of vision loss, still represents an open issue in ophthalmology and vascular medicine. Its epidemiology and management approach have not been clearly characterized yet, with several grey zones requiring investigation. Significance of RVO on cardiovascular prognosis is also unclear. “High focused Evaluation of Atherosclerotic risk profile in Retinal Thrombosis: Vascular events Incidence, Sex involvement and Interventional outcomes assessed by Ophthalmologists and internists Network” (HEART VISION) is a longitudinal, prospective, multi-center study which aims at determining the epidemiology, potentially modifiable risk factors and the determinants of RVO in an Italian-based cohort.
Methods: Enrollment of all the eligible patients presenting to recruiting centers (i.e. ophthalmology emergency room and thrombosis centers) with suspect of RVO. At baseline, all patients will undergo an opthalmologic evaluation and further investigations about cardiovascular co-morbidities and risk factors. Recruited patients will be followed for a 2-year period.
Outcome measures: Data about adverse cardiovascular events and eye-related outcomes will be recorded.
Discussion: HEART VISION will present data on prevalence and will inform on the prognosis of RVO in an Italian-based cohort. Characterization and prospective evaluation of these patients will be useful in developing novel strategies for management of RVO and their cardiovascular-related risk factors.
Ethics and dissemination: This study protocol (n. 1.0, 01.07.2014) was approved by the Sapienza-University of Rome, Ethics Board (Protocol No. 1076/14). This study will be performed in accordance with the Declaration of Helsinki. Dissemination plans include presentations at scientific conferences and publication in scientific journals.
Trial registration: ClinicalTrials.gov Identifier: NCT02257333 on October 6, 2014.

Keywords: retinal vein occlusion; vision loss; cardiovascular risk factors; ophthalmology; prospective study


How to cite this article:
Basili S, Pacella E, Pacella F, Romiti GF, Visioli G, Antonini LM, Robuffo S, Cangemi R, Mecella M, Proietti M, Raparelli V. High focused Evaluation of Atherosclerotic risk profile in Retinal Thrombosis: Vascular events Incidence, Sex involvement and Interventional outcomes assessed by Ophthalmologists and internists Network – HEART VISION study protocol. Clin Trials Degener Dis 2018;3:101-5

How to cite this URL:
Basili S, Pacella E, Pacella F, Romiti GF, Visioli G, Antonini LM, Robuffo S, Cangemi R, Mecella M, Proietti M, Raparelli V. High focused Evaluation of Atherosclerotic risk profile in Retinal Thrombosis: Vascular events Incidence, Sex involvement and Interventional outcomes assessed by Ophthalmologists and internists Network – HEART VISION study protocol. Clin Trials Degener Dis [serial online] 2018 [cited 2018 Dec 11];3:101-5. Available from: http://www.clinicaltdd.com/text.asp?2018/3/3/101/235145


  Introduction Top


Retinal vein occlusion (RVO) is a highly prevalent cause of unilateral vision loss and the second leading cause of retinal vascular disease after diabetic retinopathy.[1] Nonetheless, the epidemiology, pathophysiology and natural history of this condition have yet to be fully elucidated; besides, due to the lack of definitive data in the literature, the disease management still represents an open issue.[2]

RVO refers to a group of diseases – with different risk factors, prognosis and treatment – all characterized by impaired venous return from the retinal circulation.[3] Depending on the site of occlusion of the retinal vein, it is possible to distinguish two main clinical presentations of RVO: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), the latter representing most of the cases.[4] A pooled study, which included 11 different cohorts (with a total of 49,869 patients) showed an age and sex- standardized overall prevalence incindence of 0.52% (0.08% for CRVO and 0.42% for BRVO) – which was slightly higher in females, in Asians and Hispanics but with no significant statistical differences – and demonstrated an increased risk with age,[4] probably related to the higher burden of risk factors (RFs) and predisposing conditions.[5],[6]

It has been assumed that RVOs shares the same RFs of cardiovascular disease (e.g. arterial hypertension, diabetes, smoking, dyslipidemia, etc.).[7],[8],[9] However, RVOs, with some differences depending on the type, can also be secondary to other processes such as vasospasm, compression,[10] inflammation[11] and other conditions including thrombophilia,[12] sleep apnea[13],[14] or glaucoma[15] could also be associated. In this context, a straightforward definition of cardiovascular RFs in the disease development has not yet been provided and the impact of genetic differences, sex and sociocultural background should not be underestimated.[16] As sex (i.e. biological factors) and gender (i.e. psycho-social-cultural factors including personality traits, socioeconomic status and social relationship) are not independent, exclusively assessing one or the other fails to account for identified variations in health.[17],[18],[19],[20] Therefore, the integration of both sex and gender dimensions is a powerful tool to advance our understanding of the management and outcomes of health disease[18],[19] as it has been already proved in patients with acute coronary syndrome.[21]

A deeper knowledge on the impact of traditional and non-traditional RFs in the pathogenesis of RVO would represent a cornerstone in the improvement of primary and secondary prevention strategies, and it could help in developing a personalized management approach for the treatment of RVO patients.

Objectives of the study

The primary objectives of the study are:

  1. Creation of RVO patient’s national registry to estimate the actual prevalence of the condition.
  2. To identify the potentially modifiable RFs and to recognize further potential determinants of the disease related to sex, gender, genetics and socio-cultural background of the population.
  3. To verify the real-world management of RVO patients.
  4. To gather information for the design of IT application for the management of RVO patients.



  Methods/Design Top


Study design

The “High focused Evaluation of Atherosclerotic risk profile in Retinal Thrombosis: Vascular events Incidence, Sex involvement and Interventional outcomes assessed by Ophthalmologists and internists Network” (HEART VISION) is a longitudinal, prospective, multi-centric study in Italy [Figure 1]. According to the study design, the first step will consist in the identification of specialized services (i.e. ophthalmology emergency room and thrombosis centers) which will enroll patients accessing for suspected RVO. Each center will recruit all the eligible patients, collect written inform consent and all the relevant clinical information according to the study protocol, and will be responsible for the data-entry through the web-based platform. A physician (i.e. “local monitor”) will be responsible for the adherence to the protocol, standardized operating procedures, and for the management of critical sensitive data in accordance with the current local legislation.
Figure 1: HEART VISION study flow chart.
HEART VISION: High focused Evaluation of Atherosclerotic risk profile in Retinal Thrombosis: Vascular events Incidence, Sex involvement and Interventional outcomes assessed by Ophthalmologists and internists Network; ABI: ankle-brachial index; IMT: intimal-medial thickness; FMD: flow-mediated dilation.


Click here to view




In addition, a web-based platform will be developed to enable the management and support to surveys for medical investigation, allowing medical researchers and patients to interact using social features.

Ethical approval

This study protocol (n. 1.0, 01.07.2014) was approved by the Sapienza – University of Rome, Ethics Board (Protocol No. 1076/14). This study will be performed in accordance with the Declaration of Helsinki, and it was registered at ClinicalTrials. gov (identifier: NCT02257333).

Study population

All the eligible patients will be consecutively enrolled in the study, according to the inclusion and exclusion criteria defined below.

Inclusion/exclusion criteria

All adults aged > 18 years who access specialized centers with a suspected diagnosis of RVO, and who signed a valid inform consent will be included in the study. Patients would be excluded if a) pregnant, b) affected by a condition which would reduce the life-expectancy to less than the mean time of planned follow-up.

Baseline data collection

At baseline, and after the signature of a valid inform consent, for each patient with suspected RVO the following data will be collected: a) complete personal data and medical history (familiar, past and present) and physical assessment (anthropometric data and vital signs), b) comprehensive ophthalmologic evaluation including eye history and examination, visual acuity, eye fundus examination, optical coherent tomography (OCT) and ocular tonometry, c) data on gender-related variables (including psychosocial factors and socio-economic status), d) data on ongoing treatment and questionnaires on medications adherence,[22] demographic and social aspects (including marital status, educational level, income, working status risk taking behaviors)[23] and Mediterranean diet.[24] These data will be recorded on the online registry at baseline. Medical management and prescriptions before the confirmation of the final diagnosis will be also recorded. After 1 month from the index event, the patients will be evaluated through an outpatient examination. During the first month, the patient will undergo a specialist evaluation for the confirmation of the diagnosis (which could also include an evaluation through OCT, microperimetry and retinal fluorescein angiography). Moreover, etiologic factors and a complete evaluation of existing RFs and co-morbidities will be reassessed. At the thrombosis center, the patient will undergo the following instrumental and laboratory investigations:

  1. Assessment of the presence/absence of congenital and/or acquired thrombophilic disorders (including antiphospholipid syndrome, hyper-homocysteinemia, Factor V Leiden mutation, prothrombin mutation, protein C and S deficiencies, anti-thrombin III deficiency);
  2. Routine blood tests (including whole count cell, creatinine, prothrombin time, liver enzymes);
  3. Cardiac evaluation with electrocardiography, transthoracic echocardiography with US-Doppler evaluation (i.e. left ventricular hypertrophy screening and cardiac morphology and motility).


A subgroup of patients with an established RVO diagnosis, according to the availability and the consent of the subjects, will be involved in an ancillary evaluation of several markers of subclinical atherosclerosis and endothelial dysfunction, i.e.:

  1. Ankle-brachial index: at baseline, a measurement of upper and lower limb systolic blood pressure for ankle-brachial index calculation will be performed as previously described and a value equal or inferior to 0.90 will be considered as pathological;
  2. Carotid intimal-medial thickness (cIMT): according to the American Society of Echocardiography consensus statement on the use of carotid ultrasound to identify subclinical vascular disease, tracing far wall blood-intima and media-adventitia interfaces using leading edge–to–leading edge method at 1 cm from the carotid bulb will assess cIMT. A value of cIMT above 0.90 mm or the presence of a carotid surrounding thickening more than 1.50 mm will be defined as “pathological cIMT”;
  3. Brachial artery flow-mediated dilation (FMD): ultrasound assessment of endothelial dependent and independent FMD of brachial artery will be evaluated. Briefly, the study will be performed in a temperature-controlled room (22°C) with the subjects in a resting, supine state between the hours of 8 a.m. and 10 a.m.; brachial artery diameter will be imaged using a 7.5-MHz linear array transducer ultrasound system equipped with electronic callipers, vascular software for two-dimensional imaging, color and spectral Doppler, and internal electrocardiogram; the brachial artery will be imaged at a location 3–7 cm above the ante-cubital crease; to create a flow stimulus in the brachial artery, a sphygmomanometric cuff will be placed on the forearm; the cuff will be inflated at least 50 mmHg above systolic pressure to occlude artery inflow for 5 min; all vasodilatation measurements will be made at the end of diastole; FMD will be expressed as a change in post-stimulus diameter evaluated as a percentage of the baseline diameter;
  4. Blood and urine samples collection for the assessment of the hemostatic milieu and redox status: blood samples will be properly maintained until batch analysis in freezers at –80°C. All assays will be performed in a blinded fashion. The samples analyzed by immunoassay methods will be tested in duplicate, and those with concentrations exceeding the standard curve will be assayed again after appropriate dilution. We plan to evaluate the following parameters to study interaction between platelet function and endothelial dysfunction in RVO patients, including soluble CD40 ligand (sCD40L) and soluble P-selectin, as members of the inflammatory molecules released from platelets, plasma thromboxane B2 and von Willebrand factor as marker of endothelial activation.


Patients in which diagnosis will not be confirmed will be used as controls.

Follow-up and outcomes

Patients with an established diagnosis of RVO will be prospectively followed for 2 years.

After 3 months from the index events, a short-term follow- up will be executed to evaluate the recovery of visual acuity in relation to the type of received treatment according to the ophthalmologist clinical judgement.

Patients will be periodically evaluated with follow-up visits, and a dedicated website will be developed for their management.

The following 2-year follow up events will be collected:

  1. Major adverse cardiovascular events including ischemic heart disease (i.e. acute coronary syndrome or stable chronic angina), cerebrovascular events (including stroke or transient ischemic attack), cardiovascular death, venous thrombotic events (i.e. deep vein thrombosis and/or pulmonary embolism);
  2. Eye-related outcomes (i.e. outcomes of pharmacological and non-pharmacological management, recurrences).


Data management and statistical analysis

Dataset management and statistical analysis will be performed by both the “UOC Prima Clinica Medica – Atherothrombosis Centre at Policlinico Umberto I – Rome” and the “BioMedical Statistics and Clinical Epidemiology Centre” at Sapienza-University of Rome.

The Wilson method will be used for calculating confidence intervals (CI) for proportions. The Kaplan-Meier estimator will be used to calculate cumulative incidence, with the 95% CI. Multivariate analysis will be used in an attempt to identify determinants of outcomes and to control the effect of confounders (i.e. Cox competing risk model and logistic regression).

Likewise, the presence of the center effect will be assessed and eventually, removed. The secondary endpoints will be evaluated with the univariate log-rank test and the Cox model (with time-dependent effects) multivariate analysis. A logistic regression analysis will be performed to establish all clinical sex- and gender- related factors significantly associated with RVO.

Sample size calculation

It is planned to enroll about 1,000 patients for the study (about 50 patients per research center) during a 2-year period. An expected prevalence of 13%, which would produce a CI of 95% with amplitude of 0.043, was used for calculating the dimension of the study population. SPSS and STAT-SOFT Statistical Software will be used for performing statistical analysis.


  Discussion Top


RVO represents an important open issue of concerns for the need of a multidisciplinary approach to patient care. The disease management necessitates the involvement of physicians from a number of different clinical specialties, from ophthalmologists to vascular medicine specialists. At present, lack of definitive data on epidemiology, RFs and their specific contribution to the disease pathogenesis along with the absence of an established treatment algorithm for RVO generates some controversies. HEART VISION study will help to clarify these gray spots and overcome this potential source of pitfalls. It will pursue, as a mandatory objective, to fill in the lack of evidence on the pathogenesis of RVO and, concurrently, to bridge the gap between research and clinical practice with its prognostic and therapeutic implications. Furthermore, it will also represent the starting point for the medical community towards the development of further studies and research.


  Trial Status Top


We are currently recruiting participants.

Additional files

Additional file 1: Ethical Approval Documentation.[Additional file 1]

Additional file 2: Model consent form.[Additional file 2]

Author contributions

Study concept and design and manuscript writing: SB, EP, FP, RC, MP, VR; creation of the electronic registry of data and manuscript writing: MM; literature integration and manuscript writing: GFR, GV, LMA, SR. All authors approved the final version of the manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Financial support

This study was funded by Sapienza-University of Rome in 2014 - C26A147HC8.

Institutional review board statement

This study protocol (n. 1.0, 01.07.2014) was approved by the Sapienza-University of Rome Ethics Board (Protocol No. 1076/14). This study will be performed in accordance with the Declaration of Helsinki.

Declaration of patient consent

The authors certify that they will obtain all appropriate patient consent forms. In the form the patients will give their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity will be guaranteed.

Reporting statement

This study followed the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidance for protocol reporting.

Biostatistics statement

The statistical methods of this study were reviewed by Prof. Basili S, Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy.

Copyright license agreement

The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement

For data sharing, individual participant data will not be available. However, the study protocol and informed consent form will be made available beginning 3 months and ending 5 years following article publication to investigators whose proposed use of the data has been approved by an independent review committee identified to achieve aims in the approved proposal. In order to gain access, data requestors will need to sign a data access agreement. Proposals should be directed to stefania.basili@uniroma1.it.

Plagiarism check

Checked twice by iThenticate.

Peer review

Externally peer reviewed.

Funding: This study was funded by Sapienza-University of Rome in 2014 -C26A147HC8.

 
  References Top

1.
Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-143.  Back to cited text no. 1
    
2.
Ho M, Liu DT, Lam DS, Jonas JB. Retinal vein occlusions, from basics to the latest treatment. Retina. 2016;36:432-448.  Back to cited text no. 2
    
3.
Ip M, Hendrick A. Retinal Vein Occlusion Review. Asia Pac J Ophthalmol (Phila). 2018;7:40-45.  Back to cited text no. 3
    
4.
Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-319.  Back to cited text no. 4
    
5.
Park SJ, Choi NK, Park KH, Woo SJ. Nationwide incidence of clinically diagnosed retinal vein occlusion in Korea, 2008 through 2011: preponderance of women and the impact of aging. Ophthalmology. 2014;121:1274-1280.  Back to cited text no. 5
    
6.
Epstein D, Kvanta A, Lindqvist PG. Seasonality and incidence of central retinal vein occlusion in Sweden: a 6-year study. Ophthalmic Epidemiol. 2015;22:94-97.  Back to cited text no. 6
    
7.
Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33:901-910.  Back to cited text no. 7
    
8.
Martínez F, Furió E, Fabiá MJ, et al. Risk factors associated with retinal vein occlusion. Int J Clin Pract. 2014;68:871-881.  Back to cited text no. 8
    
9.
Khan Z, Almeida DR, Rahim K, Belliveau MJ, Bona M, Gale J. 10-Year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis. Can J Ophthalmol. 2013;48:40-45.e1.  Back to cited text no. 9
    
10.
Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999;106:2054-2062.  Back to cited text no. 10
    
11.
Yen YC, Weng SF, Chen HA, et al. Risk of retinal vein occlusion in patients with systemic lupus erythematosus: a population-based cohort study. Br J Ophthalmol. 2013;97:1192-1196.  Back to cited text no. 11
    
12.
Bucciarelli P, Passamonti SM, Gianniello F, Artoni A, Martinelli I. Thrombophilic and cardiovascular risk factors for retinal vein occlusion. Eur J Intern Med. 2017;44:44-48.  Back to cited text no. 12
    
13.
Glacet-Bernard A, Leroux les Jardins G, Lasry S, et al. Obstructive sleep apnea among patients with retinal vein occlusion. Arch Ophthalmol. 2010;128:1533-1538  Back to cited text no. 13
    
14.
Agard E, El chehab H, Vie AL, Voirin N, Coste O, Dot C. Retinal vein occlusion and obstructive sleep apnea: a series of 114 patients. Acta Ophthalmol. 2018. doi: 10.1111/aos.13798.  Back to cited text no. 14
    
15.
Na KI, Jeoung JW, Kim YK, Lee WJ, Park KH. Incidence of retinal vein occlusion in open-angle glaucoma: a nationwide, population-based study using the Korean Health Insurance Review and Assessment Database. Clin Exp Ophthalmol. 2018;46:637-644.  Back to cited text no. 15
    
16.
Spence JD, Pilote L. Importance of sex and gender in atherosclerosis and cardiovascular disease. Atherosclerosis. 2015;241:208-210.  Back to cited text no. 16
    
17.
Canadian Institute of Health Research, What is Sex? What is Gender? http://www.cihr-irsc.gc.ca/e/48642.html. Accessed September 05, 2018.  Back to cited text no. 17
    
18.
Clayton JA, Tannenbaum C. Reporting sex, gender, or both in clinical research? JAMA. 2016;316:1863-1864.  Back to cited text no. 18
    
19.
Legato MJ, Johnson PA, Manson, JE. Consideration of sex differences in medicine to improve health care and patient outcomes. JAMA. 2016;316:1865-1866.  Back to cited text no. 19
    
20.
O’Neil A, Scovelle AJ, Milner AJ, Kavanagh A. Gender/sex as a social determinant of cardiovascular risk. Circulation. 2018;137:854  Back to cited text no. 20
    
21.
Pelletier R, Khan NA, Cox J, et al. Sex versus gender-related characteristics: which predicts outcome after acute coronary syndrome in the young? J Am Coll Cardiol. 2016;67:127-135.  Back to cited text no. 21
    
22.
Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38:1363-1368.  Back to cited text no. 22
    
23.
Pelletier R, Ditto B, Pilote L. A composite measure of gender and its association with risk factors in patients with premature acute coronary syndrome. Psychosom Med. 2015;77:517-526.  Back to cited text no. 23
    
24.
Martínez-gonzález MÁ, Corella D, Salas-salvadó J, et al. Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol. 2012;41:377-385.  Back to cited text no. 24
    


    Figures

  [Figure 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Methods/Design
Discussion
Trial Status
References
Article Figures

 Article Access Statistics
    Viewed193    
    Printed2    
    Emailed0    
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]